Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.

Authors
Publication date
27 June 2017
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    National Taiwan University Repository

    redirect
    oaioai:140.112.114.62:246246/2801...
    Last time updated on 20/05/2019